Stay updated on Merck & Co. Press Releases
Sign up to get notified when there's something new on the Merck & Co. Press Releases page.
Latest updates to the Merck & Co. Press Releases page
- Check5 days agoChange DetectedMerck has announced several significant updates, including positive EU CHMP opinion for WELIREG® in treating certain tumors and advanced renal cell carcinoma, as well as promising results from the OlympiA Phase 3 trial for LYNPARZA® in early breast cancer.SummaryDifference78%
- Check12 days agoChange DetectedMerck has made significant advancements, including a 100% complete response rate in a Phase 2 trial for a lymphoma treatment and the initiation of a Phase 3 study for COVID-19 treatment, while also being recognized as one of America's Most Responsible Companies for 2025.SummaryDifference67%
- Check19 days agoNo Change Detected
- Check21 days agoChange DetectedMerck has announced its participation in the Citi 2024 Global Healthcare Conference and reported positive interim results from the pivotal Phase 3 ZENITH trial for WINREVAIR™, while also removing details about its previous participation in the Jefferies London Healthcare Conference and a licensing agreement for LM-299.SummaryDifference59%
- Check28 days agoChange DetectedMerck has made significant announcements, including the approval of WELIREG® in China for VHL disease, the recommendation to reject TRC Capital’s mini-tender offer, and the election of Surendralal Karsanbhai to its Board of Directors.SummaryDifference73%
- Check35 days agoChange DetectedMerck has received a positive EU CHMP opinion for KEYTRUDA® in treating malignant pleural mesothelioma and has entered an exclusive global license for an investigational bispecific antibody, while notable deletions include recent data on various investigational treatments and collaborations.SummaryDifference53%
- Check42 days agoChange DetectedThe website has added a comprehensive menu with sections on sustainability, research, products, and investor resources, while removing a specific news release about Merck's KEYTRUDA® treatment results.SummaryDifference49%
Stay in the know with updates to Merck & Co. Press Releases
Enter your email address, and we'll notify you when there's something new on the Merck & Co. Press Releases page.